Coherus Oncology, Inc. Common Stock
$1.35
$0.12 (+9.76%)
$1.23Day Range$1.35
Key Statistics
Market Cap
$208.58M
Shares Outstanding
154.5M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Nov 6, 2014
Round Lot
100
Locale
US
Trading Data
Day Open
$1.23
Day High
$1.35
Day Low
$1.23
Volume
3.12M
VWAP
$1.33
Prev Close
$1.23
Transactions
--
Acc. Volume
--
About Coherus Oncology, Inc. Common Stock
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836144 employeesC/O DENNIS M. LANFEAR, REDWOOD CITY, CA, 94065(650) 649-3530IPO Nov 6, 2014US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001512762
- Composite FIGI
- BBG0063N8V69
- Share Class FIGI
- BBG0063N8V87
- Ticker Root
- CHRS
- SIC Code
- 2836
About Coherus Oncology, Inc. Common Stock (CHRS) Stock
Coherus Oncology, Inc. Common Stock (CHRS) closed the 2026-09-18 session at $1.35, up 9.76% versus the previous close (+0.12). The stock opened at $1.23 and traded between $1.23 and $1.35 during that session. Session trading volume was 3.1M shares. The volume-weighted average price (VWAP) is $1.33.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
Coherus Oncology, Inc. Common Stock has a market capitalization of $208.6 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. CHRS is listed on the XNAS exchange. The company employs approximately 144 people. Coherus Oncology, Inc. Common Stock is headquartered in REDWOOD CITY, CA. The recorded listing date is 2014-11-06.
On this page you can find market CHRS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.